PRESS RELEASE published on 07/11/2024 at 07:30, 8 months 29 days ago Informations privilégiées / Autres communiqués GenSight Biologics lance une lettre d'information destinée aux investisseurs particuliers en France, présentant des actualités et des informations sur la société et ses projets innovants Investisseurs Particuliers GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Lettre D'information
PRESS RELEASE published on 07/11/2024 at 07:30, 8 months 29 days ago Inside Information / Other news releases GenSight Biologics launches a newsletter for retail investors providing updates, news articles, conferences, and financial figures in French, available via subscription on the company's website Subscription Retail Investors Newsletter French GenSight Biologics
BRIEF published on 06/20/2024 at 07:35, 9 months 19 days ago GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Gene Therapy Operational Update GenSight Biologics Financial Negotiation
BRIEF published on 06/20/2024 at 07:35, 9 months 19 days ago GenSight Biologics renégocie ses obligations financières et fournit des mises à jour opérationnelles Thérapie Génique Mise À Jour Opérationnelle Produits Biologiques GenSight Négociation Financière
PRESS RELEASE published on 06/20/2024 at 07:30, 9 months 19 days ago Inside Information / Other news releases GenSight Biologics renegotiates financial obligations and provides operational updates, with successful capital increases enhancing short-term flexibility Financial Obligations Operational Updates GenSight Biologics Capital Increases Gene Therapies
BRIEF published on 06/04/2024 at 07:35, 10 months 5 days ago GenSight Biologics fera une présentation lors de conférences médicales clés en 2024 Thérapie Génique Produits Biologiques GenSight LUMEVOQ® Conférences Médicales 2024 NOHL
BRIEF published on 06/04/2024 at 07:35, 10 months 5 days ago GenSight Biologics to Present at Key Medical Conferences in 2024 Gene Therapy GenSight Biologics Medical Conferences 2024 LUMEVOQ® LHON
PRESS RELEASE published on 06/04/2024 at 07:30, 10 months 5 days ago Informations privilégiées / Autres communiqués GenSight Biologics va présenter ses thérapies géniques innovantes pour les maladies neurodégénératives lors de conférences médicales et scientifiques importantes Thérapie Génique GenSight Biologics Maladies Neurodégénératives Conférences Médicales Présentations Scientifiques
PRESS RELEASE published on 06/04/2024 at 07:30, 10 months 5 days ago Inside Information / Other news releases GenSight Biologics to present at key medical and stakeholder meetings, including 16th Meeting of the EUNOS. Papers on LUMEVOQ® for LHON to be showcased Gene Therapy GenSight Biologics Medical Conferences LUMEVOQ Retinal Neurodegenerative Diseases
BRIEF published on 06/03/2024 at 07:35, 10 months 6 days ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
Published on 04/09/2025 at 09:00, 56 minutes ago Touchstone Exploration Announces Changes to Its Board of Directors
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Ondine Biomedical Inc. - Economic Study Suggests c.£200 Million UK Savings
Published on 04/09/2025 at 07:40, 2 hours 16 minutes ago RTG Mining Inc. Announces Issue Of A$4.2 million Chess Depository Instruments Under Placement
Published on 04/09/2025 at 04:00, 5 hours 56 minutes ago QNX Now Powering WeRide's Next-Generation ADAS Platform
Published on 04/08/2025 at 22:47, 11 hours 9 minutes ago MicroVision Announces Retail Investor Day in Redmond, WA on May 20, 2025
Published on 04/09/2025 at 09:37, 18 minutes ago Partec AG: ParTec AG announces major participation in advancing Europe’s Digital Autonomy in HPC and AI with the DARE SGA1 Project
Published on 04/09/2025 at 09:24, 31 minutes ago H&R GmbH & Co. KGaA publishes Annual Report and Sustainability Report for FY 2024
Published on 04/09/2025 at 09:06, 49 minutes ago EQS-Adhoc: swissnet Group announces delisting of its shares from Euronext Access+ Paris
Published on 04/09/2025 at 09:05, 51 minutes ago More Impact AG introduces Z-Boxx as an innovative smoking cessation product
Published on 04/09/2025 at 09:00, 55 minutes ago Original-Research: Multitude SE (von NuWays AG): BUY
Published on 04/09/2025 at 09:00, 56 minutes ago STEF : Avis de mise à disposition des comptes annuels 2024
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Museum Studio becomes a majority shareholder in Lord Cultural Resources
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Museum Studio devient actionnaire majoritaire de Lord Cultural Resources
Published on 04/09/2025 at 07:00, 2 hours 56 minutes ago Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
Published on 04/09/2025 at 07:00, 2 hours 56 minutes ago Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
